Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for the Treatment of Opioid Use Disorder
NCT06639464Phase 2Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in opioid use disorder (OUD), sponsored by Brigham and Women's Hospital. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06639464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639464.